New drug CAY001 enters first human tests – no benefit expected
Knowledge-focused
Recruiting now
This early-stage study is the first time the experimental drug CAY001 is given to humans. It will involve 24 healthy volunteers aged 18-50 to check the drug's safety, how the body processes it, and what side effects may occur. Participants receive a single dose by IV and are moni…
Phase: PHASE1 • Sponsor: Cayuga Biotech, Inc. • Aim: Knowledge-focused
Last updated May 26, 2026 04:06 UTC